Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - 1st line (L1), ... vs. nivolumab based treatment, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.22; 2.06]
1.59 [1.22 ; 2.06 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 631 NA not evaluable deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.31; 1.92]
1.59 [1.31 ; 1.92 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 631 NA not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.89 [1.56; 2.28]
1.89 [1.56 ; 2.28 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 631 NA not evaluable progression or deaths (PFS)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.75 [1.32; 2.33]
1.75 [1.32 ; 2.33 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 631 NA not evaluable objective responses (ORR)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.29 [0.17; 0.49]
0.29 [0.17 ; 0.49 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 631 NA not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.28 [0.20; 0.41]
0.28 [0.20 ; 0.41 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 631 NA not evaluable TRAE (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.99 [0.63; 1.56]
0.99 [0.63 ; 1.56 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.97; 2.03]
1.40 [0.97 ; 2.03 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.88; 2.21]
1.40 [0.88 ; 2.21 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.93 [1.14; 3.27]
1.93 [1.14 ; 3.27 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07]
4.05 [0.18 ; 90.07 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
0.50 [0.05 ; 5.56 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
0.50 [0.02 ; 15.03 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
2.02 [0.18 ; 22.39 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 8.64 [2.57; 29.01]
8.64 [2.57 ; 29.01 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58]
0.25 [0.01 ; 5.58 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.08 [0.92; 4.69]
2.08 [0.92 ; 4.69 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
0.50 [0.02 ; 15.03 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.20; 5.03]
1.01 [0.20 ; 5.03 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89]
5.10 [0.59 ; 43.89 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.67 [0.11; 4.03]
0.67 [0.11 ; 4.03 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.26 [0.34; 4.75]
1.26 [0.34 ; 4.75 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.86 [0.39; 1.88]
0.86 [0.39 ; 1.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
0.50 [0.05 ; 5.56 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
0.50 [0.02 ; 15.03 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07]
4.05 [0.18 ; 90.07 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
1.01 [0.06 ; 16.16 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
1.01 [0.06 ; 16.16 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89]
5.10 [0.59 ; 43.89 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
1.01 [0.02 ; 50.88 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
0.50 [0.02 ; 15.03 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
1.01 [0.06 ; 16.16 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
2.02 [0.07 ; 60.32 ] CheckMate 067 (N vs I ; all population), 2015 (REV) 1 0% 624 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 02:59 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 285,68,127,128
- treatments: 329